Can dasatinib treat chronic myelogenous leukemia?

Chronic myeloid leukemia (CML) is a chronic leukemia caused by genetic mutations in stem cells in the bone marrow. It is characterized by the presence of abnormally proliferating granulocytes in the bone marrow, ultimately leading to the presence of abnormal white blood cells in the peripheral blood. Dasatinib (Dasatinib) is a targeted therapy drug mainly used to treat CML and some acute lymphoblastic leukemias (ALL).

As a tyrosine kinase inhibitor, dasatinib (Startase) can effectively inhibit the kinase activity of the BCR-ABL fusion protein, which is the causative gene of CML. BCR-ABLThe abnormal activity of the fusion protein leads to abnormal cell proliferation and survival signaling, thereby promoting the growth and spread of leukemia cells. By inhibiting the activity of BCR-ABL fusion protein, dasatinib (Startase) can effectively control the condition of CML, reduce the number of abnormally proliferating granulocytes in the bone marrow, restore normal hematological parameters, and prolong the survival time of patients.

Clinical studies have shown that dasatinib (Stacer) has shown good efficacy and safety in the treatment of CML patients. Patients usually need to take dasatinib (Dasatinib) long-term until a sustained complete or partial molecular response is achieved and remains stable with ongoing monitoring. For patients with CML, dasatinib (Startaxed) has been widely used as a first-line treatment and has also been used to treat patients with relapsed /refractory CML. In addition, Dasatinib (Startase) is also used to treat certain types of ALL, specifically Philadelphiachromosome-positive (Ph+) ALL.

Therefore, althoughdasatinib (Startaxed) is mainly used to treat CML and some ALL patients, it is also considered one of the effective treatments for chronic myelogenous leukemia. The patient is takingDasatinib (Startase)During this period, the doctor's recommendations should be closely followed, and clinical and molecular monitoring should be performed regularly to evaluate the treatment effect and adjust the treatment plan in order to obtain the best treatment results.